Regenacy Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company developing treatments for peripheral neuropathies, hemoglobinopathies and certain oncology indications based on regeneration of normal protein function with oral, isoform selective histone deacetylase enzyme ("HDAC") inhibitors. The company's selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy's programs selectively inhibit histone deacetylase 6 (HDAC6) to restore normal protein and organelle intracellular transport in diabetic and other peripheral neuropathies and inhibit HDACs 1 and 2 to restore oxygen transport in orphan blood disorders such as sickle cell disease and beta-thalassemia, regenerate normal cognitive function in patients with psychiatric disorders, and restore normal white blood cell function in acute myeloid leukemia (AML).
Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer’s Association International Conference
Regenacy Pharmaceuticals Appoints Simon S. Jones as President and Chief Executive Officer
Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model
Regenacy Pharmaceuticals HDAC1,2 Inhibitors Demonstrate Single-agent and Synergistic Activity with Azacitidine (Vidaza®) in Preclinical Models of Acute Myeloid Leukemia
Regenacy Pharmaceuticals to be Launched by Acetylon Pharmaceuticals and Celgene Corporation Agrees to Complete Acquisition of Acetylon